Sizing up the Next Generation of Nanomedicines.

ABSTRACT: During the past two decades the nanomedicine field has experienced significant progress. To date, over sixty nanoparticle (NP) formulations have been approved in the US and EU while many others are in clinical or preclinical development, indicating a concerted effort to translate promising bench research to commercially viable pharmaceutical products. The use of NPs as novel drug delivery systems, for example, can improve drug safety and efficacy profiles and enable access to intracellular domains of diseased cells, thus paving the way to previously intractable biological targets. However, the measurement of their physicochemical properties presents substantial challenges relative to conventional injectable formulations. In this perspective, we focus exclusively on particle size, a core pr

SUBMITTER: Clogston JD 

PROVIDER: S-EPMC7274461 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature